Thursday 18 December 2014

Roche in $550m deal for superbug antibiotic

Swiss drugmaker Roche will pay up to 500 million Swiss francs ($548 million) for an experimental antibiotic, marking a rare foray by a major pharmaceutical firm into the battle against so-called "superbug" infections found in hospitals


'Superbugs' deemed urgent threats

Antibiotic-resistant gonorrhea, a diarrhea-causing superbug and a class of fast-growing killer bacteria dubbed a "nightmare" have been classified as urgent public health threats in the US.


Short antibiotic courses ‘safer’

Short courses of antibiotics appear just as effective as longer ones – and a great deal safer – in treating respiratory infections that might cause pneumonia in children on temporary breathing devices, said a report. A study by Johns Hopki

 1 2 3 4 5 >  Last ›

calendarCalendar of Events